Evaluation of methotrexate pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia

This study explores how genetic variations affect methotrexate clearance and transport in relation to neurotoxicity in children with acute lymphoblastic leukemia (ALL). The researchers analyzed 97 methotrexate pharmacogenomic variants in 763 children with ALL. They found that rs17222723 in ABCC2 and rs1045642 in ABCB1 were nominally associated with neurotoxicity susceptibility. However, pharmacogenomic variants did not significantly improve neurotoxicity risk stratification. Overall, the study suggests that associations between neurotoxicity susceptibility and methotrexate pharmacogenomic variants are modest.